Only two months after snagging $150 million from investors, Septerna has added another $47.5 million to the pile courtesy of a Vertex licensing deal.

Vertex, Inc. (NASDAQ:VERX) nosedived by 18.98 percent on Thursday to finish at $34.54 apiece as investors sold off positions following a disappointing earnings performance last year.

As Vertex looks to tap into the Middle Eastern market of around 23,000 patients—on top of its estimated patient pool of 35,000 in the U.S. and Europe—the drugmaker remains “confident in ...

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma Kewalramani, M.D., to $21.5 million, according to the company’s proxy filing.

Vertex Pharmaceuticals' non-opioid painkiller significantly decreased pain in patients with diabetes suffering from chronic nerve pain in a mid-stage trial, fueling efforts to develop a treatment ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2025, and raised the low end of its ...

That is a question posed by the latest deal by Vertex, which is paying ImmunoGen $15 million upfront to explore the use of ADCs with its near-approval CRISPR/Cas9 therapy exagamglogene autotemcel.